secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001104659-25-002023
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus promotes James Young to CFO; appoints new CCO and Chief of Clinical Operations
--------------------------------------------------------------------------------

- James Young promoted to CFO, effective Jan 6, 2025; annual base salary $420k, target bonus 50%.
- Sean Murphy transitions to Chief Manufacturing, Strategy and Business Development Officer; remains on board.
- Richard Marshak appointed Chief Commercial Officer; Jodi Devlin appointed Chief of Clinical Operations.
- Executive officers elected to forgo $515k in salary for RSUs under new Salary Investment Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465925002023/0001104659-25-002023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465925002023/tm252133d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer